$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
艾乐替尼降低ALk阳性肺癌患者死亡的风险
2025-10-19 11:44:20
Check Details
特罗凯针对肺癌脑转移患者效果好
2025-10-19 11:44:20
Check Details
克唑替尼治疗ALK阳性NSCLC疗效优于化疗
2025-10-19 11:44:20
Check Details
服用艾乐替尼多久会出现耐药?
2025-10-19 11:44:20
Check Details
肺癌靶向药物吉非替尼和特罗凯的区别
2025-10-19 11:44:20
Check Details
艾乐替尼治疗ALK阳性NSCLC客观缓解率达93.5
2025-10-19 11:44:20
Check Details
奥希替尼获批治疗EGFR敏感突变的患者
2025-10-19 11:44:20
Check Details
艾乐替尼用于治疗克唑替尼耐药的患者
2025-10-19 11:44:20
Check Details
阿法替尼比一代EGFR TKI作用强度更大
2025-10-19 11:44:20
Check Details
试验证明,色瑞替尼治疗NSCLC更具优势
2025-10-19 11:44:20
Check Details
卡博替尼用于治疗RET基因重排肺癌患者
2025-10-19 11:44:20
Check Details
阿来替尼治疗ALK阳性NSCLC疗效非凡
2025-10-19 11:44:20
Check Details
1
2
...
2990
2991
2992
2993
2994
2995
2996
...
4153
4154
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Elacestrant: Precision Therapy for ESR1-Mutant Resistant HR+/HER2- Advanced Breast Cancer
2
Selpercatinib Complete Medication Guide: Indications, Dosage and Safety Information for RET Inhibitor
3
Complete Guide to Dosage and Dose Adjustment of Entrectinib
4
Comprehensive Analysis of Bleeding Risk with Tepotinib in MET-Mutated Non-Small Cell Lung Cancer
5
Lomustine vs Temozolomide: Comprehensive Comparison of Efficacy and Safety in Glioma Treatment
6
Tepotinib and Osimertinib: Current Status and Clinical Positioning of Combination Therapy in Non-Small Cell Lung Cancer
7
Tumor Shrinkage Effect and Core Therapeutic Value of Pazopanib
8
Tabrecta (Capmatinib): A Targeted Therapy for METex14-Mutated NSCLC
9
Pazopanib Shows Promise as Second-Line Therapy for Aggressive Skin Cancer
10
Managing Immunotherapy-Related Adverse Events of Tarlatamab-Imdelltra: A Guide to Dual-Specific T Cell Engager Safety
11
Almonertinib Safety Guide: Managing Adverse Reactions in NSCLC Treatment with a 3rd-Gen EGFR TKI
12
Pimitespib Storage Guidelines: Temperature, Humidity & Light Control for Home Use